Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely, J., et al.
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.
Marshall, A. D., et al.
Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy.
Grebely, J., et al.
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
Midgard, H., et al.
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.
Grebely, J., et al.
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
Grebely, J., et al.
Topics
Fact sheets
- Addiction,
- Ars Medici,
- BMC Cancer,
- BMC Family Practice,
- BMC Infectious Diseases,
- BMC Public Health,
- European Addiction Research,
- Infectious Diseases and Therapy,
- International Journal of Drug Policy,
- Journal of Clinical Virology,
- Journal of Viral Hepatitis,
- Liver International,
- Medizin Forum,
- Open Forum Infectious Diseases,
- Praxis,
- Primary & Hospital Care,
- Sucht,
- Suchtmagazin,
- Swiss Medical Forum,
- The Journal of Clinical Pharmacology,
- The Lancet Gastroenterology and Hepatology
